This case report describes the occurrence of hyperbilirubinemia as a complication of
metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated …

Here, we report the case of a patient, diagnosed with BRAF V600E-mutated metastatic
malignant melanoma M1a, who achieved a complete metabolic response after 7 months of …

The prognosis of metastatic melanoma has changed markedly in recent years because of
the advent of newer targeted therapies such as BRAF inhibitors. However, the response to …

Tumoral melanosis describes a pigmented lesion clinically suspicious for melanoma but
characterized histopathologically by aggregates of melanin-laden macrophages without …

Objective: Adverse events of drug therapy Background: Combination therapy with BRAF
V600E inhibitor dabrafenib and MEK inhibitor trametinib significantly improves progression …

A middle‐aged female with metastatic melanoma was found to have hemoperitoneum after
starting systemic therapy with the BRAF and MEK inhibitors dabrafenib and trametinib …

Purpose To report the overall survival (OS) and clinical characteristics of BRAF inhibitor–
naive long-term responders and survivors treated with dabrafenib plus trametinib in a phase …

Combination therapy using a BRAF and MEK inhibitor significantly improves both
progression-free and overall survival in patients with BRAF V600-mutated stage IV …

Introduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in
overall survival, progression‐free survival, and response rates in patients with metastatic …

Introduction Patients with distant metastatic melanoma has a poor prognosis, with a reported
median survival time of six to eight months. In modern era, survival has prolonged with the …